The EPO Board of Appeal's recent revocation of the CRISPR-Cas9 patent has brought a lot of attention. However, it's not
March 2020
The EPO Board of Appeal's recent revocation of the CRISPR-Cas9 patent has brought a lot of attention. However, it's not the only CRISPR-related IP issue to watch out for in Europe this year. Read HGF Patent Director @emma_longland article in @IAM_magazine: lnkd.in/d_4f7pk